Patents by Inventor Frederic Gilbert
Frederic Gilbert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230118871Abstract: A sealing assembly (1) for a turbine engine comprising a first element (2) and a second element (3), the first and second elements (2, 3) being concentric and in relative rotational movement with respect to each other about an axis of rotation (X), the sealing assembly (1) comprising at least one first wiper (4a) and an abradable member (5), the first wiper (4a) being annular in shape and carried by the first element (2), the first wiper (4a) extending radially towards the abradable member (5) and continuously around the axis of rotation (X), the abradable member (5) being annular in shape and carried by the second element (3), the abradable member (5) extending tangentially opposite the first wiper (4a), the first wiper (4a) comprising primary angular portions (11), each extending tangentially along a primary angular sector (11?), the primary angular portions (11) each having, in cross-section, a first constant profile, characterised in that the first wiper (4a) comprises secondary angular portions (13) eachType: ApplicationFiled: April 1, 2021Publication date: April 20, 2023Inventors: Teddy Frederic Gilbert CHANTRAIT, Antoine Robert Alain BRUNET, Mael THEVENOT, Gilles Jean-Luc DESSEIN, Jean-Yves Fernand PARIS, Vincent Gilbert Alex WAGNER
-
Publication number: 20220227751Abstract: A compound according to Formula Ia: wherein L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis, lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.Type: ApplicationFiled: November 12, 2021Publication date: July 21, 2022Applicant: GALAPAGOS NVInventors: Frédéric Gilbert LABÉGUÈRE, Gregory John Robert NEWSOME, Luke Jonathan ALVEY, Laurent Raymond Maurice SANIÈRE, Stephen Robert FLETCHER
-
Publication number: 20220144823Abstract: The present invention discloses compounds according to Formula I: wherein R1, R2, R3a, R3b, Het, X and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of endocrine, nutritional, metabolic, and/or cardiovascular diseases by administering the compound of the invention.Type: ApplicationFiled: February 17, 2020Publication date: May 12, 2022Inventors: Stéphane Nicolas Alain BEAUMONT, Xavier Marie BOCK, Daniel COMAS MARTINEZ, Agnès Marie JONCOUR, Frédéric Gilbert LABÉGUÈRE, Miriam LÓPEZ RAMOS, Taoues TEMAL-LAÏB
-
Patent number: 11220499Abstract: A compound according to Formula Ia: wherein L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis, lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.Type: GrantFiled: May 4, 2018Date of Patent: January 11, 2022Assignee: GALAPAGOS NVInventors: Frédéric Gilbert Labéguère, Gregory John Robert Newsome, Luke Jonathan Alvey, Laurent Raymond Maurice Sanière, Stephen Robert Fletcher
-
Patent number: 10829478Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, R6a, R6b, the subscript n and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering the compound of the invention.Type: GrantFiled: June 1, 2017Date of Patent: November 10, 2020Assignee: GALAPAGOS NVInventors: Frédéric Gilbert Labéguère, Rama Heng, Frédéric André De Ceuninck, Luke Jonathan Alvey, David Amantini, Franck Laurent Brebion, Pierre Marc Marie Joseph Deprez, Romain Luc Marie Gosmini, Hélène Marie Jary, Christophe Peixoto, Iuliana Ecaterina Pop-Botez, Marie Laurence Claire Varin
-
Patent number: 10550100Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, R6, Cy, and the subscript n are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering the compound of the invention.Type: GrantFiled: June 1, 2017Date of Patent: February 4, 2020Assignee: GALAPAGOS NVInventors: Frédéric Gilbert Labéguère, Rama Heng, Frédéric André De Ceuninck, Luke Jonathan Alvey, David Amantini, Franck Laurent Brebion, Pierre Marc Marie Joseph Deprez, Romain Luc Marie Gosmini, Hélène Marie Jary, Christophe Peixoto, Iuliana Ecaterina Pop-Botez, Marie Laurence Claire Varin
-
Patent number: 10508111Abstract: The present invention discloses compounds according to Formula I: wherein R1, R2, and Cy are as defined herein. The present invention relates to compounds inhibiting IRAK family kinases, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoimmune diseases and/or proliferative diseases by administering the compound of the invention.Type: GrantFiled: October 14, 2016Date of Patent: December 17, 2019Assignee: GALAPAGOS NVInventors: Reginald Christophe Xavier Brys, Raphaël Jean Joël Geney, Agnès Marie Joncour, Julien Georges Pierre-Olivier Doyon, Frédéric Gilbert Labéguère, Jean-Michel Lefrançois, Oscar Mammoliti, Benoît Antoine Schmitt, Steven Emiel Van Der Plas, Christel Jeanne Marie Menet
-
Publication number: 20190315719Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, R6a, R6b, the subscript n and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering the compound of the invention.Type: ApplicationFiled: June 1, 2017Publication date: October 17, 2019Inventors: Frédéric Gilbert LABÉGUÈRE, Rama HENG, Frédéric André DE CEUNINCK, Luke Jonathan ALVEY, David AMANTINI, Franck Laurent BREBION, Pierre Marc Marie Joseph DEPREZ, Romain Luc Marie GOSMINI, Hélène Marie JARY, Christophe PEIXOTO, Iuliana Ecaterina POP-BOTEZ, Marie Laurence Claire VARIN
-
Publication number: 20190300503Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, R6, Cy, and the subscript n are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering the compound of the invention.Type: ApplicationFiled: June 1, 2017Publication date: October 3, 2019Inventors: Frédéric Gilbert LABÉGUÈRE, Rama HENG, Frédéric André DE CEUNINCK, Luke Jonathan ALVEY, David AMANTINI, Franck Laurent BREBION, Pierre Marc Marie Joseph DEPREZ, Romain Luc Marie GOSMINI, Hélène Marie JARY, Christophe PEIXOTO, Iuliana Ecaterina POP-BOTEZ, Marie Laurence Claire VARIN
-
Publication number: 20190002458Abstract: A compound according to Formula Ia: wherein L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis, lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.Type: ApplicationFiled: May 4, 2018Publication date: January 3, 2019Applicant: GALAPAGOS NVInventors: Frédéric Gilbert LABÉGUÈRE, Gregory John Robert NEWSOME, Luke Jonathan ALVEY, Laurent Raymond Maurice SANIÈRE, Stephen Robert FLETCHER
-
Publication number: 20180305351Abstract: The present invention discloses compounds according to Formula I: wherein R1, R2, and Cy are as defined herein. The present invention relates to compounds inhibiting IRAK family kinases, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoimmune diseases and/or proliferative diseases by administering the compound of the invention.Type: ApplicationFiled: October 14, 2016Publication date: October 25, 2018Inventors: Reginald Christophe Xavier BRYS, Raphaël Jean Joël GENEY, Agnès Marie JONCOUR, Julien Georges Pierre-Olivier DOYON, Frédéric Gilbert LABÉGUÈRE, Jean-Michel LEFRANÇOIS, Oscar MAMMOLITI, Benoît Antoine SCHMITT, Steven Emiel VAN DER PLAS, Christel Jeanne Marie MENET
-
Patent number: 10047083Abstract: A compound according to Formula Ia: wherein L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis, lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.Type: GrantFiled: December 11, 2015Date of Patent: August 14, 2018Assignee: GALAPAGOS NVInventors: Frédéric Gilbert Labéguère, Gregory John Robert Newsome, Luke Jonathan Alvey, Laurent Raymond Maurice Sanière, Stephen Robert Fletcher
-
Publication number: 20180016275Abstract: A compound according to Formula Ia: wherein Cy, L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis), lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.Type: ApplicationFiled: May 30, 2017Publication date: January 18, 2018Applicant: GALAPAGOS NVInventors: Frédéric Gilbert LABÉGUÈRE, Gregory John Robert NEWSOME, Luke Jonathan ALVEY, Laurent Raymond Maurice SANIÈRE, Stephen Robert FLETCHER
-
Patent number: 9708312Abstract: A compound according to Formula (Ia), wherein Cy, L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula (I) that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis), lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.Type: GrantFiled: December 17, 2013Date of Patent: July 18, 2017Assignee: GALAPAGOS NVInventors: Frédéric Gilbert Labéguère, Gregory John Robert Newsome, Luke Jonathan Alvey, Laurent Raymond Maurice Sanière, Stephen Robert Fletcher
-
Publication number: 20160244442Abstract: A compound according to Formula Ia: wherein L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis, lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.Type: ApplicationFiled: December 11, 2015Publication date: August 25, 2016Applicant: GALAPAGOS NVInventors: Frédéric Gilbert LABÉGUÈRE, Gregory John Robert NEWSOME, Luke Jonathan ALVEY, Laurent Raymond Maurice SANIÈRE, Stephen Robert FLETCHER
-
Patent number: 9296116Abstract: The invention relates to a manual cutting tool including two jaws each provided with a cutting blade, the two jaws being mounted movable in rotation with respect to a securing system so as to define a closed position and an open position of a cutting area. The tool also includes two cams mounted rotating with respect to the two jaws and each including an aperture, and a bearing surface having a variable curvature, the two bearing surfaces being configured so as to be in permanent connection. The tool includes two connection parts positioned on the axes of rotation of the jaws and configured to connect the cams to the jaws.Type: GrantFiled: March 25, 2014Date of Patent: March 29, 2016Assignee: FISKARS FRANCE SASInventors: Frédéric Gilbert Descombes, Chris Thelisson
-
Patent number: 9296100Abstract: The invention relates to a handle for a hand-operated striking tool including a body having a striking end corresponding to a terminal area. The handle also includes a connection system configured to surround the terminal area of the body at a distance so as to define a space between the connection system and body. The connection system includes at least one access hole to the body on each front surface in the terminal area of the body. At least two securing members are configured to be inserted in the holes of the connection system and to mechanically connect a striking head to the body in an orthogonal direction to the striking head.Type: GrantFiled: January 31, 2014Date of Patent: March 29, 2016Assignee: FISKARS FRANCE SASInventors: Frédéric Gilbert Descombes, Chris Thelisson, Serge Gouverneur
-
Publication number: 20160039807Abstract: A compound according to Formula (Ia), wherein Cy, L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula (I) that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis), lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.Type: ApplicationFiled: December 17, 2013Publication date: February 11, 2016Applicant: GALAPAGOS NVInventors: Frédéric Gilbert LABÉGUÈRE, Gregory John Robert NEWSOME, Luke Jonathan ALVEY, Laurent Raymond Maurice SANIÈRE, Stephen Robert FLETCHER
-
Patent number: 9255095Abstract: A compound according to Formula Ia: wherein L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis, lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.Type: GrantFiled: January 6, 2014Date of Patent: February 9, 2016Assignee: GALAPAGOS NVInventors: Frédéric Gilbert Labéguère, Gregory John Robert Newsome, Luke Jonathan Alvey, Laurent Raymond Maurice Sanière, Stephen Robert Fletcher
-
Patent number: 9222905Abstract: Device for the selective detection of benzene gas, which comprises, on a base substrate, a combination of at least one functionalized multi- or single-wall carbon nanotube sensor decorated with rhodium clusters, and at least one functionalized multi- or single-wall carbon nanotube sensor decorated with metal clusters selected from gold, palladium, nickel and titanium, and/or undecorated, where said substrate additionally comprises means for measuring the variation in the resistance of said sensors. The device is useful at ambient temperature in the presence or absence of oxygen and easy to handle. It also relates to a method for the manufacturing thereof and for detecting the gas in the chemical industry, the petrochemical industry, petrol stations, or household, aeronautical or research applications.Type: GrantFiled: November 2, 2010Date of Patent: December 29, 2015Assignees: Universitat Rovira I Virgili, Sensotran, S.L., University Of Namur, Centre de Recherche Public—Gabriel Lippmann, Université Libre de BruxellesInventors: Eduard Llobet Valero, Radouane Leghrib, Marc Delgado Olivella, Jean-Jacques Pireaux, Alexandre Felten, Jérôme Guillot, Henri-Nöel Migeon, Ali Mansour, François Amand Baudouin Reniers, Nicolas Yves Claessens, Frédéric Gilbert Michel Demoisson